Where Global Innovation
and Capital Meet

Page 2

Exscientia expands IPO to over $350m

The cancer drug developer has closed its initial public offering after underwriters exercised the greenshoe option.

Oct 7, 2021

Pyxis picks price range

UChicago spinout Pyxis Oncology is aiming to raise more than $153m in its initial public offering, having set a price range of $14 to $16.

Oct 5, 2021

Exscientia establishes Nasdaq listing

The Dundee spinout has raised more than $304m in its IPO in the US, with another $160m secured through a concurrent private placement.

Oct 4, 2021

Li-S Energy celebrates market debut

Based on research at Deakin University, Li-S Energy has gone public on the Australian Stock Exchange after raising $25m in its initial public offering.

Sep 30, 2021

Lucid Diagnostics lines up IPO

Case Western Reserve University-linked Lucid Diagnostics is seeking an initial public offering that would net it up to $57.5m.

Sep 28, 2021

Oxford Nanopore sets IPO plans in motion

Oracle has signed up to be a cornerstone investor for Oxford Nanopore’s initial public offering, putting up half of the $410m target.

Sep 21, 2021

Prenetics tests out $1.25bn reverse merger

Genetic testing services provider Prenetics, a spinout of City University of Hong Kong, will hold a reverse merger at a $1.25bn valuation.

Sep 17, 2021

Context Therapeutics frames IPO plans

Based on research at Drexel University, Context Therapeutics is seeking to raise up to $21m in an initial public offering on Nasdaq.

Sep 15, 2021

Exscientia explores Nasdaq IPO

Dundee spinout Exscientia is continuing a busy fundraising year with a filing for an IPO in the US and a $35m concurrent private placement.

Sep 13, 2021

© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here